Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555835 | 0.84 | KDM4E (0.62) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| SCHEMBL2299271 | 0.82 | ALOX5 (0.67) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| SCHEMBL14215697 | 0.82 | MAPT (0.59) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| SCHEMBL17774881 | 0.79 | P2RX1 (0.60) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| SCHEMBL15894582 | 0.79 | ALOX5 (0.63) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| Mesalamine SCHEMBL28187698 | 0.79 | KDM4E (0.96) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| SCHEMBL9312494 | 0.79 | EGFR (0.61) | ALOX5KDM4EHIF1AALDH1A1PTGS2 | |
| SCHEMBL16589373 | 0.78 | CASP1 (0.45) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| SCHEMBL1977469 | 0.78 | ALOX5 (0.61) | ALOX5KDM4ETDP1HIF1AALDH1A1 | |
| SCHEMBL9363663 | 0.78 | ALOX5 (1.00) | ALOX5KDM4ETDP1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2020056044-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | Singular Genomics Systems, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | disclosed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | disclosed |
| US-20030171260-A1 | Compositions and methods utilizing hydroxamates to scavenge oxidant toxins | NELSON DEANNA JEAN (US) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | ALOX5 2705/4885KDM4E 4603/4885TDP1 4868/4885 |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | ALOX5 2274/4885KDM4E 4435/4885TDP1 4867/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | ALOX5 428/4885KDM4E 4571/4885TDP1 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.